Ram Sasisekharan
Director/Board Member at Harvard Mit Health Sciences & Technology
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Langer | M | 74 |
David H. Koch Institute for Integrative Cancer Research
 David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | 46 years |
| Nicholas G. Galakatos | M | 66 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Phillip Sharp | M | 79 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Terry McGuire | M | 68 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Tuan Ha-Ngoc | M | 72 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Michael Cima | M | 64 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| K. Wittrup | M | - |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Jo-Ann Beltramello | F | - | 17 years | |
| Ian D. Fier | M | - | 22 years | |
| James Collins | M | 58 |
Harvard Mit Health Sciences & Technology
| - |
| Utkan Demirci | M | - |
Harvard Mit Health Sciences & Technology
| - |
| David Sabatini | M | - |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Paula Hammond | M | 60 |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Matthew Vander Heiden | M | - |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
| Lisa Schwarz | F | - |
David H. Koch Institute for Integrative Cancer Research
David H. Koch Institute for Integrative Cancer Research Miscellaneous Commercial ServicesCommercial Services David H. Koch Institute for Integrative Cancer Research operates a research facility for cancer cure development. The company was founded in 2007 and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alan Crane | M | 60 |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Craig Wheeler | M | 63 | 14 years | |
| Christopher Guiffre | M | 56 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Ganesh Venkataraman Kaundinya | M | 57 | 17 years | |
| Christoph Westphal | M | 56 | 5 years | |
| Oliver Fetzer | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 years |
| Paul Friedman | M | 81 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| Tyler Ellis | M | - |
Massachusetts Institute of Technology
| 7 years |
| Bruce Downey | M | 76 | 11 years | |
| William Rastetter | M | 75 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| Russ Spieler | M | - |
Massachusetts Institute of Technology
| 5 years |
| Vishal Kapur | M | - |
Massachusetts Institute of Technology
| 5 years |
| Luke Chellis | M | - |
Massachusetts Institute of Technology
| 5 years |
| Ji Zhang | M | - |
Massachusetts Institute of Technology
| 5 years |
| Tiffany Crowell | F | - |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| J. P. Michael Motion | M | - |
Massachusetts Institute of Technology
| 6 years |
| Rodrigo Canales | M | - |
Massachusetts Institute of Technology
| 5 years |
| Earl Jones | M | - |
Massachusetts Institute of Technology
| 3 years |
| Huan Liu | M | - |
Massachusetts Institute of Technology
| 5 years |
| Tom Gray | M | - |
Massachusetts Institute of Technology
| 6 years |
| Nathan Hans Vantzelfde | M | - |
Massachusetts Institute of Technology
| 5 years |
| Alexandre Santos | M | - |
Massachusetts Institute of Technology
| 4 years |
| Patrick Michael McCaney | M | 43 |
Massachusetts Institute of Technology
| 5 years |
| Hatice Hale Özsoy Biyikli | F | 47 |
Massachusetts Institute of Technology
| 4 years |
| Rahul Agrawal | M | 44 |
Massachusetts Institute of Technology
| 5 years |
| Mira Wilczek | F | 42 |
Massachusetts Institute of Technology
| 2 years |
| Timothy Heidel | M | - |
Massachusetts Institute of Technology
| 9 years |
| Mona Vernon | F | - |
Massachusetts Institute of Technology
| 6 years |
| Frederick Daso | M | - |
Massachusetts Institute of Technology
| 10 years |
| Fernando Mier-Hicks | M | - |
Massachusetts Institute of Technology
| 4 years |
| Yan Jia Liu | M | 40 |
Massachusetts Institute of Technology
| 5 years |
| Francis O'Sullivan | M | - |
Massachusetts Institute of Technology
| 2 years |
| Vaughn Mandy | F | - |
Massachusetts Institute of Technology
| 6 years |
| Kathleen Schwind | F | - |
Massachusetts Institute of Technology
| 4 years |
| Tian Hang Hu | M | 46 |
Massachusetts Institute of Technology
| 5 years |
| Cynthia Clarke | F | - |
Massachusetts Institute of Technology
| 1 years |
| Ted Tomlinson | M | - |
Massachusetts Institute of Technology
| 5 years |
| Ram Woo | M | - |
Massachusetts Institute of Technology
| 5 years |
| Feyza Haskaraman | F | - |
Massachusetts Institute of Technology
| 4 years |
| Carlo Tursi | M | 41 |
Massachusetts Institute of Technology
| 9 years |
| Celine Fung | F | - |
Massachusetts Institute of Technology
| 2 years |
| David Quiram | M | 49 |
Massachusetts Institute of Technology
| 5 years |
| Bryce Kim | M | - |
Massachusetts Institute of Technology
| 12 years |
| Paul Witinski | M | - |
Massachusetts Institute of Technology
| 2 years |
| Paul Schimmel | M | 83 | - | |
| Santiago Jesus López de Haro | M | - |
Massachusetts Institute of Technology
| 2 years |
| Paritosh Somani | M | - |
Massachusetts Institute of Technology
| 4 years |
| David Berry | M | 47 |
Massachusetts Institute of Technology
| 8 years |
| Kevin Wang | M | - |
Massachusetts Institute of Technology
| 5 years |
| Rory Edwards | M | - |
Massachusetts Institute of Technology
| 7 years |
| Steve Hall | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 6 years |
| Karen L. Roberts | F | 67 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 years |
| Alexander M. Sauer-Budge | M | - |
Massachusetts Institute of Technology
| 3 years |
| Ben Shapiro | M | 84 | 13 years | |
| Richard Shea | M | 72 | 13 years | |
| Mia Y. Qian | M | - |
Massachusetts Institute of Technology
| 5 years |
| Bruce A. Leicher | M | 68 | 10 years | |
| Peter Hutt | M | 89 | 13 years | |
| John Clarke | M | 70 | 13 years | |
| James Sulat | M | 73 | 11 years | |
| Robert Tepper | M | 68 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 years |
| Lisa Carron Shmerling | F | 63 | - | |
| James E. O'Neill | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Jim Walker | M | - |
Massachusetts Institute of Technology
| 1 years |
| Wesley Chan | M | - |
Massachusetts Institute of Technology
| 5 years |
| Elizabeth Stoner | M | 73 | 13 years | |
| Rebeca Hwang | M | - |
Massachusetts Institute of Technology
| 5 years |
| Andy Wheeler | M | 45 |
Massachusetts Institute of Technology
| 5 years |
| Marsha Fanucci | F | 70 | 11 years | |
| Neena Kadaba | M | - |
Massachusetts Institute of Technology
| 5 years |
| Janet Yoo | F | - |
Massachusetts Institute of Technology
| 7 years |
| Alice Chiang | F | - |
Massachusetts Institute of Technology
| 4 years |
| Raphi Schorr | M | - |
Massachusetts Institute of Technology
| 6 years |
| Jonathan Lii | M | - |
Massachusetts Institute of Technology
| 4 years |
| Susan Kelley | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 3 years |
| Matthew S. Reynolds | M | - |
Massachusetts Institute of Technology
| 5 years |
| Alexander Taussig | M | - |
Massachusetts Institute of Technology
| 2 years |
| Jamie Flinchbaugh | M | - |
Massachusetts Institute of Technology
| 2 years |
| Kareem Akhtar | M | - |
Massachusetts Institute of Technology
| 5 years |
| Michael Speerschneider | M | - |
Massachusetts Institute of Technology
| 4 years |
| Rachel Sheinbein | F | - |
Massachusetts Institute of Technology
| 2 years |
| Ammar Alali | M | - |
Massachusetts Institute of Technology
| 5 years |
| Lisa Jakobovits | F | - |
Massachusetts Institute of Technology
| 4 years |
| Kin Yee Pong | M | 47 |
Massachusetts Institute of Technology
| 4 years |
| Saagar Kamal Gupta | M | - |
Massachusetts Institute of Technology
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ram Sasisekharan
- Personal Network
